RPL17 and neoplasm: Although it is possible to act on each therapeutic level during these phases, the strategies that have reached the clinic to date and have yielded initially successful results are monoclonal antibodies that block immune checkpoints CTLA-4 and PD-1, which control activation of the immune response at peripheral lymphoid organs and tumor level, respectively [9].